Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) posted its quarterly earnings results on Tuesday. The company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.21 by $0.06, FiscalAI reports. Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. The business had revenue of $214.27 million during the quarter, compared to analyst estimates of $207.12 million.

Kiniksa Pharmaceuticals International Stock Up 1.9%

NASDAQ KNSA opened at $43.61 on Tuesday. The firm has a market cap of $3.34 billion, a PE ratio of 58.93 and a beta of 0.06. The company has a 50 day moving average price of $45.94 and a 200 day moving average price of $42.86. Kiniksa Pharmaceuticals International has a 52 week low of $21.25 and a 52 week high of $50.03.

Insider Activity

In related news, CAO Michael R. Megna sold 6,625 shares of the business’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $46.69, for a total transaction of $309,321.25. Following the completion of the transaction, the chief accounting officer owned 27,418 shares in the company, valued at $1,280,146.42. The trade was a 19.46% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry D. Quart sold 12,528 shares of the business’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $45.27, for a total transaction of $567,142.56. Following the transaction, the director owned 12,546 shares of the company’s stock, valued at approximately $567,957.42. This trade represents a 49.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 61,479 shares of company stock worth $2,832,812 over the last 90 days. 53.48% of the stock is currently owned by insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

Large investors have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC increased its stake in Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares in the last quarter. Osaic Holdings Inc. acquired a new position in Kiniksa Pharmaceuticals International during the 2nd quarter valued at approximately $31,000. Smartleaf Asset Management LLC acquired a new position in Kiniksa Pharmaceuticals International during the 4th quarter valued at approximately $36,000. CIBC Private Wealth Group LLC acquired a new position in Kiniksa Pharmaceuticals International during the 4th quarter valued at approximately $41,000. Finally, Quantbot Technologies LP acquired a new position in Kiniksa Pharmaceuticals International during the 2nd quarter valued at approximately $43,000. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Analysts Set New Price Targets

KNSA has been the subject of several recent research reports. Wells Fargo & Company boosted their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Canaccord Genuity Group initiated coverage on shares of Kiniksa Pharmaceuticals International in a report on Thursday, February 19th. They issued a “buy” rating and a $62.00 price target for the company. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a report on Sunday. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Friday, April 17th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Tuesday, April 21st. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.00.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.